Serial Blood and Salivary Sampling for Validation of Quantitative Amifostine Assays
Currently, there are no published methods for easily determining the level of amifostine in
the blood or saliva. A method has been developed within the Department of Radiation Oncology
by Drs. Douglas Spitz and Gurminder Sidhu, within the Spitz Lab. This method has been tested
using both animal sampling and expired blood (obtained from DeGowin blood center) mixed with
If the method proves successful, it could then be used as a tool to quantify blood and
salivary amifostine levels and possibly correlate them to treatment efficacy or limiting
adverse events using amifostine. A better method of treatment, either increasing the
efficacy of amifostine or reducing its unwanted side effects, could then be developed.
Amifostine is an FDA-approved medication that protects the lining of the mucous membranes of
the head and neck when radiation treatments are given. Normally, amifostine is injected into
a vein causing side effects of nausea, vomiting and low blood pressure. The amifostine can
reduce radiation side effects but does not remove them completely.
Time Perspective: Prospective
John M. Buatti, M.D.
University of Iowa Hospitals & Clinics
United States: Institutional Review Board
|University of Iowa Department of Radiation Oncology||Iowa City, Iowa 52242|